Wall Street Zen cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Free Report) from a hold rating to a sell rating in a research report report published on Saturday.
A number of other equities analysts have also recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, October 8th. Barclays initiated coverage on Corvus Pharmaceuticals in a report on Monday, October 13th. They issued an “overweight” rating and a $16.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.75.
Check Out Our Latest Stock Report on Corvus Pharmaceuticals
Corvus Pharmaceuticals Stock Performance
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03. On average, analysts predict that Corvus Pharmaceuticals will post -0.63 EPS for the current fiscal year.
Hedge Funds Weigh In On Corvus Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the business. Shelton Wealth Management LLC acquired a new position in Corvus Pharmaceuticals in the third quarter valued at $101,000. China Universal Asset Management Co. Ltd. increased its stake in Corvus Pharmaceuticals by 20.2% in the second quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company’s stock valued at $62,000 after purchasing an additional 2,599 shares during the last quarter. Squarepoint Ops LLC increased its stake in Corvus Pharmaceuticals by 37.0% in the second quarter. Squarepoint Ops LLC now owns 138,462 shares of the company’s stock valued at $554,000 after purchasing an additional 37,430 shares during the last quarter. Sender Co & Partners Inc. acquired a new position in Corvus Pharmaceuticals in the second quarter valued at $52,000. Finally, Perceptive Advisors LLC acquired a new position in Corvus Pharmaceuticals in the second quarter valued at $5,754,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
See Also
- Five stocks we like better than Corvus Pharmaceuticals
- What is Insider Trading? What You Can Learn from Insider Trading
- Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet
- What is the Nasdaq? Complete Overview with History
- 3 High-Yield Banks for Investors to Buy on the Dip
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 5 Surprising Stocks Set to Benefit From a Future Robotics Boom
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.